KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Twist Bioscience (TWST) Operating Expenses (2018 - 2025)

Historic Operating Expenses for Twist Bioscience (TWST) over the last 8 years, with Q4 2025 value amounting to $136.6 million.

  • Twist Bioscience's Operating Expenses rose 1073.39% to $136.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $526.1 million, marking a year-over-year decrease of 234.2%. This contributed to the annual value of $512.8 million for FY2025, which is 392.92% down from last year.
  • Latest data reveals that Twist Bioscience reported Operating Expenses of $136.6 million as of Q4 2025, which was up 1073.39% from $128.9 million recorded in Q3 2025.
  • Twist Bioscience's 5-year Operating Expenses high stood at $170.4 million for Q2 2024, and its period low was $69.2 million during Q1 2021.
  • In the last 5 years, Twist Bioscience's Operating Expenses had a median value of $119.6 million in 2023 and averaged $115.4 million.
  • As far as peak fluctuations go, Twist Bioscience's Operating Expenses surged by 6070.81% in 2021, and later plummeted by 2594.64% in 2025.
  • Quarter analysis of 5 years shows Twist Bioscience's Operating Expenses stood at $98.0 million in 2021, then grew by 0.93% to $98.9 million in 2022, then rose by 19.83% to $118.5 million in 2023, then rose by 4.12% to $123.4 million in 2024, then increased by 10.73% to $136.6 million in 2025.
  • Its Operating Expenses stands at $136.6 million for Q4 2025, versus $128.9 million for Q3 2025 and $126.2 million for Q2 2025.